Deutsche Bank (DE:DBKGn) analyst Pito Chickering maintained a Hold rating on Edwards Lifesciences on Wednesday, setting a price target of $113, which is approximately 5.41% below the present share price of $119.46.
Chickering expects Edwards Lifesciences to post earnings per share (EPS) of $0.55 for the fourth quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Edwards Lifesciences, with an average price target of $126.5.
The analysts price targets range from a high of $135 to a low of $113.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $1.31 billion and a net profit of $396.1 million. The company's market cap is $74.58 billion.
According to TipRanks.com, Deutsche Bank analyst Pito Chickering is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 9.0% and a 49.30% success rate.
Incorporated in 1958, California-based Edwards Lifesciences Corp (NYSE:EW). is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.